PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.76
Ask: 7.50
Change: 1.24 (21.53%)
Spread: 0.74 (10.947%)
Open: 5.72
High: 7.22
Low: 5.72
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Total Voting Rights

30 Jun 2009 09:56

RNS Number : 7642U
Synairgen plc
30 June 2009
Ā 

ļ»æ

30Ā JuneĀ 2009

Synairgen plc

("Synairgen" or "the Company")

Total Voting Rights

Ā 

For the purposes of the Financial Services Authority's disclosure and Transparency Rules, the Company's total issued shareĀ capital at the date of this notice isĀ 59,745,249.Ā 

The Company's issued share capital consists ofĀ 59,745,249Ā ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company is thereforeĀ 59,745,249.

The above figure ofĀ 59,745,249Ā may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

For more informationĀ pleaseĀ contact:

Ā 

Synairgen plcĀ  Tel: + 44 (0) 2380 512 800

Richard Marsden, Managing Director

John Ward, Finance Director

Matrix Corporate CapitalĀ  Tel: + 44 (0) 20 3206 7000

Alastair Stratton

Anu Tayal

Threadneedle CommunicationsĀ  Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
TVRCKKKPFBKKAAN
Date   Source Headline
17th Mar 20227:25 amRNSSynairgen Provides Update on ACTIV-2 Trial
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
11th Mar 20224:40 pmRNSSecond Price Monitoring Extn
11th Mar 20224:35 pmRNSPrice Monitoring Extension
8th Mar 20224:35 pmRNSHolding(s) in Company
8th Mar 20223:52 pmRNSHolding(s) in Company
4th Mar 20221:36 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSUpdate on SNG001
24th Feb 202211:30 amRNSHolding(s) in Company
23rd Feb 202211:25 amRNSHolding(s) in Company
21st Feb 20227:00 amRNSTopline results from Phase 3 SPRINTER trial
4th Feb 20224:54 pmRNSHolding(s) in Company
28th Jan 20227:00 amRNSDirector/PDMR Shareholding
19th Jan 20222:05 pmRNSHolding(s) in Company
12th Jan 202211:53 amRNSHolding(s) in Company
7th Jan 20225:25 pmRNSHolding(s) in Company
6th Jan 202212:00 pmRNSSynairgen announces partnership with Ashfield
23rd Dec 20214:15 pmRNSHolding(s) in Company
23rd Dec 20212:19 pmRNSHolding(s) in Company
21st Dec 20215:05 pmRNSHolding(s) in Company
8th Dec 20217:00 amRNSData Presented at ESWI Influenza Conference
6th Dec 20215:30 pmRNSHolding(s) in Company
6th Dec 20217:00 amRNSSynairgen Presents SNG001 Data at ESWI
19th Nov 20212:26 pmRNSHolding(s) in Company
11th Nov 20217:00 amRNSSynairgen completes Phase III recruitment
8th Nov 202112:58 pmRNSHolding(s) in Company
26th Oct 20213:13 pmRNSHolding(s) in Company
21st Oct 20215:39 pmRNSHoldings in Company
21st Oct 20217:00 amRNSGrant of Options
20th Oct 20217:00 amRNSSNG001 progresses to Phase 3 of ACTIV-2 trial
13th Oct 20217:00 amRNSSynairgen appoints Gareth Walters, Ph.D. as CRO
5th Oct 202111:25 amRNSHolding(s) in Company
30th Sep 20217:02 amRNSNon-Executive Director Appointment
30th Sep 20217:00 amRNSInterim results
21st Sep 20217:00 amRNSSynairgen Notice of Interim Results
10th Sep 202111:30 amRNSHolding(s) in Company
12th Aug 20214:12 pmRNSExercise of Options and Total Voting Rights
6th Aug 202112:21 pmRNSHolding(s) in Company
29th Jun 20214:28 pmRNSHolding(s) in Company
18th Jun 202110:29 amRNSResult of AGM
7th Jun 20217:00 amRNSGrant of Options
25th May 20214:28 pmRNSNotice of AGM
24th May 20217:00 amRNSResults of in vitro studies
12th May 20217:00 amRNSFull Year Results
30th Apr 20217:00 amRNSHome Cohort data of SG016 Phase II trial
16th Apr 20214:37 pmRNSHolding(s) in Company
15th Apr 202111:44 amRNSHolding(s) in Company
6th Apr 20214:36 pmRNSHolding(s) in Company
15th Feb 20217:00 amRNSDosing commenced in US ACTIV-2 trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.